Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature

Biomaterials

Volumn 35, Issue 5, 2014, Pages 1643-1656

  Barui, Sugata ^a   Saha, Soumen ^a,d   Mondal, Goutam ^a,b   Haseena, Shaik ^a,c   Chaudhuri, Arabinda ^a,d  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^c SP Biotech Park   (India)

^d ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Anti angiogenic chemotherapy; Curcumin doxorubicin synergy; Pegylated RGDK lipopeptide; Targeting tumor vasculature; Tumor growth inhibition

Indexed keywords

CANCER THERAPEUTICS; CURCUMIN-DOXORUBICIN SYNERGY; HYDROPHILIC AND HYDROPHOBIC; PEGYLATED; SMALL MOLECULES; TUMOR GROWTH; TUMOR VASCULATURE; TUMOR VASCULATURE TARGETING;

CHEMOTHERAPY; DISEASES; ENDOTHELIAL CELLS; LIPOSOMES; MAMMALS; ONCOLOGY;

TUMORS;

CD31 ANTIGEN; CURCUMIN; DOXORUBICIN; INTEGRIN RECEPTOR; LIPOPEPTIDE; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURFACE CHARGE; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME; ZETA POTENTIAL;

MUS;

ANTI-ANGIOGENIC CHEMOTHERAPY; CURCUMIN-DOXORUBICIN SYNERGY; PEGYLATED RGDK-LIPOPEPTIDE; TARGETING TUMOR VASCULATURE; TUMOR GROWTH INHIBITION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELLS, CULTURED; CURCUMIN; DOXORUBICIN; FLOW CYTOMETRY; HUMANS; LIPOPEPTIDES; LIPOSOMES; MICE; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84890245521     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.10.074     Document Type: Article

References (44)

1. Fan X., Zhang C., Liu D.B., Yan J., Liang H.P. The clinical applications of curcumin: current state and the future. Curr Pharm Des 2013, 19:2011-2031.
2. Liu H.S., Ke C.S., Cheng H.C., Huang C.Y., Su C.L. Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A. Mol Pharmacol 2011, 80:638-646.
3. Singh M., Singh N. Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells. Mol Cell Biochem 2011, 347:1-11.
4. Wu S.H., Hang L.W., Yang J.S., Chen H.Y., Lin H.Y., Chiang J.H., et al. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways. Anticancer Res 2010, 30:2125-2133.
5. Datta R., Halder S.K., Zhang B. Role of TGF-β signaling in curcumin-mediated inhibition of tumorigenicity of human lung cancer cells. JCancer Res Clin Oncol 2013, 139(4):563-572.
6. Bisht S., Mizuma M., Feldmann G., Ottenhof N.A., Hong S.M., Pramanik D., et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther 2010, 9:2255-2264.
7. Li L., Ahmed B., Mehta K., Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007, 6:1276-1282.
8. Safavy A., Raisch K.P., Mantena S., Sanford L.L., Sham S.W., Krishna N.R., et al. Design and development of water-soluble curcumin conjugates as potential anticancer agents. JMed Chem 2007, 50:6284-6288.
9. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
10. Gou M.L., Men K., Shi H.S., Xiang M.L., Zhang J., Song J., et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy invitro and invivo. Nanoscale 2011, 3:1558-1567.
11. Gong C., Deng S., Wu Q., Xiang M., Wei X., Li L., et al. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials 2013, 34:1413-1432.
12. Mohanty C., Acharya S., Mohanty A.K., Dilnawaz F., Sahoo S.K. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (London) 2010, 5:433-449.
13. Mohanty C., Sahoo S.K. The invitro stability and invivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010, 31:6597-6611.
14. Reuter S., Charlet J., Juncker T., Teiten M.H., Dicato M., Diederich M. Effect of curcumin on nuclear factor kappaB signaling pathways in human chronic myelogenous K562 leukemia cells. Ann NY Acad Sci 2009, 1171:436-447.
15. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., Limtrakul P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002, 64:573-582.
16. Romiti N., Tongiani R., Cervelli F., Chieli E. Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci 1998, 62:2349-2358.
17. Misra R., Sahoo S.K. Coformulation of doxorubicin and curcumin in poly(d, l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 2011, 8:852-866.
18. Ganta S., Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharmaceutics 2009, 6:928-939.
19. Duan J., Mansour H.M., Zhang Y., Deng X., Chen Y., Wang J., et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharmaceutics 2012, 426:193-201.
20. Sung B., Kunnumakkara A.B., Sethi G., Anand P., Guha S., Aggarwal B.B. Curcumin circumvents chemoresistance invitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009, 8(4):959-970.
21. Yu L.L., Wu J.G., Dai N., Yu H.G., Si J.M. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-κB transcription factor. Oncol Rep 2011, 26(5):1197-1203.
22. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
23. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17:1359-1370.
24. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
25. Pramanik D., Majeti B.K., Mondal G., Karmali P.P., Sistla R., Ramprasad O.G., et al. Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic α5β1 integrin receptor and mouse tumor vasculature. JMed Chem 2008, 51:7298-7302.
26. Samanta S., Sistla R., Chaudhuri A. The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth. Biomaterials 2010, 31:1787-1797.
27. Tsuchida K., Sunada Y., Noji S., Murakami T., Uezumi A., Nakatani M. Inhibitors of the TGF-beta superfamily and their clinical applications. Mini Rev Med Chem 2006, 6:1255-1261.
28. Saunier E.F., Akhurst R.J. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 2006, 6:565-578.
29. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
30. Pramanik D., Campbell N.R., Das S., Gupta S., Chenna V., Bisht S., et al. Acomposite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 2012, 3:640-650.
31. Mayer L.D., Bally M.B., Cullis P.R. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 1986, 857:123-126.
32. Mayer L.D., Tai L.C., Ko D.S., Masin D., Ginsberg R.S., Cullis P.R., et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989 Nov 1, 49(21):5922-5930.
33. Mondal G., Barui S., Chaudhuri A. The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor. Biomaterials 2013, 34:6249-6260.
34. Li G., Zhang L., Chen E., Wang J., Jiang X., Chen J.H., et al. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity. Cancer Res 2010, 70:10243-10254.
35. Magnussen A., Kasman I.M., Norberg S., Baluk P., Murray R., McDonald D.M. Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res 2005, 65:2712-2721.
36. Filyak Y., Filyak O., Souchelnytskyi S., Stoika R. Doxorubicin inhibits TGF-β signaling in human lung carcinoma A549 cells. Eur J Pharmacol 2008, 590:67-73.
37. Massague J., Blain S., Lo R. TGFβ signaling in growth control, cancer and heritable disorders. Cell 2000, 103:295-309.
38. Souchelnytskyi S. Transforming growth factor-β signaling and its role in cancer. Exp Oncol 2002, 24:3-12.
39. Akhurst R.J., Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012, 11:790-811.
40. Derynck R., Zhang Y. Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 2003, 425:577-584.
41. Shi Y., Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
42. ten Dijke P., Hill C. New insights into TGF-β-Smad signaling. Trends Biochem Sci 2004, 29:265-273.
43. Reguly T., Wrana J. In or out? The dynamics of Smad nucleocytoplasmic shuttling. Trends Cell Biol 2003, 13:216-220.
44. Zawel L., Dai J., Buckhaults P., Zhou S., Kinzler K.W., Vogelstein B., et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998, 1:611-617.